Effects of KRN4884 (a Novel K^+ Channel Opener), Leveromakalim, Nilvadipine and Propranolol on Endothelin : 1 : Induced Heart Disorders in Anesthetized Rats
スポンサーリンク
概要
- 論文の詳細を見る
The effects of KRN4884 (5-amino-N-[2-(2-chrolophenyl)ethyl]-N′-cyano-3-pyridinecarboxamidine), a novel K+ channel opener, on the electrocardiogram changes caused by the intracoronary administration of endothelin-1 (ET-1) were studied in anesthetized rats and compared with the effects of levcromakalim, a K+ channel opener; nilvadipine, a Ca2+ antagonist; and propranolol, a β-adrenoceptor antagonist. KRN4884 (50 μg/kg, i.v.) and levcromakalim (300 μg/kg, i.v.) inhibited the ST segment elevation and the development of arrhythmias induced by ET-1 (5 μg, i.c.) and decreased the incidence of death. Nilvadipine (300 μg/kg, i.v.) and propranolol (1000 and 3000 μg/kg, i.v.) each prevented the ST segment elevation, but the suppressions of the occurrence of arrhythmias produced by nilvadipine and propranolol were less than that shown by KRN4884. KRN4884 (30 and 50 μg/kg, i.v.), levcromakalim (100 and 300 μg/kg, i.v.) and nilvadipine (100 and 300 μg/kg, i.v.) significantly decreased the mean blood pressure in a dose-dependent manner, but propranolol did not. The heart rate was decreased by nilvadipine (100 and 300 μg/kg, i.v.) and propranolol (1000 and 3000 μg/kg, i.v.), but was not affected by KRN4884 (30 and 50 μg/kg, i.v.) or levcromakalim (100 and 300 μg/kg, i.v.). These results suggest that pretreatments with KRN4884 and levcromakalim are more effective on ET-1-induced electrocardiogram changes than those with nilvadipine and propranolol.
- 社団法人 日本薬理学会の論文
- 1998-11-01
著者
-
Kawahara Jun-ichi
日本製薬工業協会
-
Kawahara Jun-ichi
Pharmaceutical Development Lab. Kirin Brewery Co. Ltd.
-
Kawahara Jun-ichi
Pharmaceutical Development Laboratory Kirin Brewery Co. Ltd.
-
HARADA Katsuhiko
Pharmaceutical Development Laboratory, Kirin Brewery Co., Ltd.
-
OKADA Yuji
Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd.
-
UZUMAKI Hiroya
Pharmaceutical Development Laboratory, Kirin Brewery Co., Ltd.
-
KUSAKA Masaru
Pharmaceutical Development Laboratory, Kirin Brewery Co., Ltd.
-
TOKIWA Tomonobu
Pharmaceutical Development Laboratory, Kirin Brewery Co., Ltd.
-
Kusaka Masaru
Pharmaceutical Development Laboratory Kirin Brewery Co. Ltd.
-
Uzumaki Hiroya
Pharmaceutical Development Laboratory Kirin Brewery Co. Ltd.
-
Tokiwa T
Pharmaceutical Development Laboratory Kirin Brewery Co. Ltd.
-
Okada Yuji
参天製薬
-
Okada Yuji
Pharmaceutical Laboratory Kirin Brewery Co. Ltd.
-
Harada Katsuhiko
Pharmaceutical Development Laboratories Kirin Brewery Co. Ltd.
関連論文
- 220 THE APPEARANCE MECHANISM OF ATYPICAL CREATINE KINASE ISOENZYME IN RAT PLASMA
- 103 CLINICAL APPLICATION OF PLASMA CK AND LDH ISOENZYMES : Investigation of isoproterenol- and adriamycin-induced cardiac damage in rats
- Effects of KRN4884 (a Novel K^+ Channel Opener), Leveromakalim, Nilvadipine and Propranolol on Endothelin : 1 : Induced Heart Disorders in Anesthetized Rats
- The mechanism of rat-cataractogenesis with the organ culture in low-calcium medium (GENERAL TOXICITY) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)
- Transient expression of type I collagen in glomeruli with anti-Thy-1 antibody-induced mesangial proliferative lesions
- Chemical Modification of Recombinant Human Granulocyte Colony-Stimulating Factor by Polyethylene Glycol Increases its Biological Activity in vivo
- Involvement of the TGF-β1 Derived from Megakaryocyte in the PEG-rHuMGDF-Induced Myelofibrosis and Bone Formation
- PHARMACOKINETICS OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (KRN8601) IN THE RAT
- PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
- Evaluation of lung toxicity using bleomycin-induced lung injury model rat.(GENERAL SESSION BY ORAL PRESENTATION)(GENERAL TOXICITY & NERVOUS SYSTEM)
- PEG-rHuMGDF Causes Osteogenesis by Stimulating Osteoblast Differentiation and Inhibiting Osteoclast Differentiation in Normal Mice
- Mechanism of Action of KRN2391 in Canine Coronary Vascular Bed.
- Effect of KRN2391, a Novel Vasodilator, on Various Experimental Anginal Models in Rats.